Back to top
more

EyePoint Pharmaceuticals (EYPT)

(Real Time Quote from BATS)

$17.93 USD

17.93
214,761

+0.33 (1.88%)

Updated May 1, 2024 01:47 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Compared to Estimates, EyePoint Pharmaceuticals (EYPT) Q4 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for EyePoint Pharmaceuticals (EYPT) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Will EyePoint Pharmaceuticals (EYPT) Report Negative Q4 Earnings? What You Should Know

by Zacks Equity Research

EyePoint Pharmaceuticals (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vericel Corporation (VCEL) Q4 Earnings Beat Estimates

by Zacks Equity Research

Vericel Corporation (VCEL) delivered earnings and revenue surprises of 44.44% and 0%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Here's Why Momentum in EyePoint Pharmaceuticals (EYPT) Should Keep going

by Zacks Equity Research

EyePoint Pharmaceuticals (EYPT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Are You Looking for a Top Momentum Pick? Why EyePoint Pharmaceuticals (EYPT) is a Great Choice

by Zacks Equity Research

Does EyePoint Pharmaceuticals (EYPT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Wall Street Analysts Think EyePoint Pharmaceuticals (EYPT) Could Surge 31.27%: Read This Before Placing a Bet

by Zacks Equity Research

The consensus price target hints at a 31.3% upside potential for EyePoint Pharmaceuticals (EYPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Here's What Could Help EyePoint Pharmaceuticals (EYPT) Maintain Its Recent Price Strength

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, EyePoint Pharmaceuticals (EYPT) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Exelixis (EXEL) Tops Q4 Earnings Estimates

by Zacks Equity Research

Exelixis (EXEL) delivered earnings and revenue surprises of 6.45% and 0.33%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

EyePoint Pharmaceuticals (EYPT) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research

Does EyePoint Pharmaceuticals (EYPT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Wall Street Analysts Believe EyePoint Pharmaceuticals (EYPT) Could Rally 77.05%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 77.1% in EyePoint Pharmaceuticals (EYPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

What Makes EyePoint Pharmaceuticals (EYPT) a Good Fit for 'Trend Investing'

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, EyePoint Pharmaceuticals (EYPT) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Biotech Stock Roundup: EXEL Partners RCUS for Study, PHVS & EYPT Gain on Study Data

by Zacks Equity Research

Updates from Exelixis (EXEL) and Pharvaris (PHVS) are in the spotlight this week.

EyePoint (EYPT) Surges 178% on Upbeat Phase II Eye Disease Data

by Zacks Equity Research

EyePoint (EYPT) announces positive top-line data from the phase II study of its investigational candidate, EYP-1901, in the treatment of wet age-related macular degeneration. The stock rallies 178%.

Does EyePoint Pharmaceuticals (EYPT) Have the Potential to Rally 336.07% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 336.1% in EyePoint Pharmaceuticals (EYPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -248.78% and 88.48%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Gilead Sciences (GILD) Q1 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Gilead (GILD) delivered earnings and revenue surprises of -15.95% and 0.52%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in EyePoint Pharmaceuticals (EYPT): Can Its 9.6% Jump Turn into More Strength?

by Zacks Equity Research

EyePoint Pharmaceuticals (EYPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Strength Seen in Acadia (ACAD): Can Its 5.0% Jump Turn into More Strength?

by Zacks Equity Research

Acadia (ACAD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Down -32.42% in 4 Weeks, Here's Why You Should You Buy the Dip in EyePoint Pharmaceuticals (EYPT)

by Zacks Equity Research

EyePoint Pharmaceuticals (EYPT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 3.17% and 8.48%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 30% and 0.48%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Repligen (RGEN) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Repligen (RGEN) delivered earnings and revenue surprises of 13.24% and 4.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Provention Bio, Inc. (PRVB): Can Its 25.7% Jump Turn into More Strength?

by Zacks Equity Research

Provention Bio, Inc. (PRVB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Alcon (ALC) Clareon Suite to Get a Boost With Product Launch

by Zacks Equity Research

With the latest launch of Clareon Toric, Alcon's (ALC) Clareon Collection of IOLs is complete in the United States.

    EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 8.77% and 2.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?